Novavax Stock News

Investors bid up the shares after a prominent public figure tested positive for COVID-19. First lady Jill Biden made the news this week after she developed symptoms for the second time.

This growth in Novavax (NVAX) is likely due to the rising COVID-19 infection cases in the United States. Management claims its updated vaccine is effective against the newly emerged virus variants.

The U.S. is reporting increases in positive coronavirus tests and in coronavirus hospitalizations. Pfizer, Moderna, and Novavax are readying their updated vaccines for the fall vaccination season.

As the market heats up, it's time to start to look for undervalued short squeeze candidates Citigroup  believes that the S&P 500 index has a target of 5,000 in 2024. This is likely considering the po

Here's a look at 3 biotech short squeeze candidates. For investors looking for short-term gains, technical analysis provides key insights on potential entry and exit points.

COVID-19 cases have been on the rise, and the CDC expects hospitalizations will increase. Novavax's updated vaccine has been effective against new variants and could offer protection.

Short selling is a risky strategy that involves betting against a stock's price, hoping that it will fall and generate profits for the trader. However, when a stock rises instead of falls, short selle

President Biden has requested additional funding for new coronavirus vaccines. He plans to encourage people in this country to receive these shots.

The COVID-19 virus is evolving in white-tailed deer at triple the rate it evolves in humans–and future changes could have serious consequences for people as well as livestock, according to a study p

There's no way to predict with 100% accuracy what stocks will face short squeezes or when they could happen. However, companies with high short interest and potential business tailwinds are prime cand

The updated Covid vaccines from Pfizer, Moderna and Novavax still need green lights from the FDA and the CDC before they roll out to the public.

In studies on small animals and primates, Novavax's (NVAX) updated monovalent COVID-19 vaccine generates a robust immune response against the currently dominating Eris variant.

Biotech company Novavax Inc (NYSE:NVAX) announced that its Covid vaccine is effective against the Eris variant.

The Nasdaq has taken a rather large hit in recent weeks, sinking about 7.5% between July 18 and Aug 17. Two of the main reasons for the decline are worries about U.S. inflation and the Chinese econom

Drugmakers like Pfizer and Moderna tamped down expectations. Now, cases are increasing.